Luke Utley

TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.

TL;DR: Using real-time mass spectroscopy in a hairless mouse skin model, substantial penetration is confirmed of a 20% DEET standard and a commercially marketed sunscreen formulation had a 6-fold more rapid detection and 3.4-fold greater penetration at steady state.

TL;DR: In this paper, the compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer, provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl.

TL;DR: These first-in-human, Phase I, randomized, double-blind, placebo-controlled single (SAD) and multiple ascending dose (MAD) studies are to identify a safe and pharmacodynamically-active dose and schedule for AG-348 to be used in subsequent clinical studies in subjects with PKD.

TL;DR: A first-in-man Phase I study of oral AG-221 was designed to evaluate the safety, PK, and PD, including 2-HG levels, as well as clinical activity, in patients with advanced IDH2 mutant positive hematologic malignancies.